These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 20224056)

  • 1. Outcomes of thrombolytic therapy for acute ischemic stroke in Chinese patients: the Taiwan Thrombolytic Therapy for Acute Ischemic Stroke (TTT-AIS) study.
    Chao AC; Hsu HY; Chung CP; Liu CH; Chen CH; Teng MM; Peng GS; Sheng WY; Hu HH;
    Stroke; 2010 May; 41(5):885-90. PubMed ID: 20224056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombolysis for acute ischaemic stroke with alteplase in an Asian population: results of the multicenter, multinational Safe Implementation of Thrombolysis in Stroke-Non-European Union World (SITS-NEW).
    Rha JH; Shrivastava VP; Wang Y; Lee KE; Ahmed N; Bluhmki E; Hermansson K; Wahlgren N;
    Int J Stroke; 2014 Oct; 9 Suppl A100():93-101. PubMed ID: 22988894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Acute management and research of stroke in Taiwan: an update].
    Chung CP; Hu HH
    Rinsho Shinkeigaku; 2010 Nov; 50(11):828-9. PubMed ID: 21921457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of Renal Impairment on Outcome for Thrombolysis-Treated Acute Ischemic Stroke: ENCHANTED (Enhanced Control of Hypertension and Thrombolysis Stroke Study) Post Hoc Analysis.
    Carr SJ; Wang X; Olavarria VV; Lavados PM; Rodriguez JA; Kim JS; Lee TH; Lindley RI; Pontes-Neto OM; Ricci S; Sato S; Sharma VK; Woodward M; Chalmers J; Anderson CS; Robinson TG;
    Stroke; 2017 Sep; 48(9):2605-2609. PubMed ID: 28739832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different doses of recombinant tissue-type plasminogen activator for acute stroke in Chinese patients.
    Chao AC; Liu CK; Chen CH; Lin HJ; Liu CH; Jeng JS; Hu CJ; Chung CP; Hsu HY; Sheng WY; Hu HH;
    Stroke; 2014 Aug; 45(8):2359-65. PubMed ID: 24994721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Different Dosages of Alteplase in Atrial Fibrillation-Related Acute Ischemic Stroke After Intravenous Thrombolysis: A Nationwide, Multicenter, Prospective Cohort Study in Taiwan.
    Lin SF; Chen CF; Hu HH; Ho BL; Chen CH; Chan L; Lin HJ; Sun Y; Lin YY; Chen PL; Lin SK; Wei CY; Lin YT; Lee JT; Chao AC;
    J Am Heart Assoc; 2022 Feb; 11(3):e023032. PubMed ID: 35048714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The combined approach to lysis utilizing eptifibatide and rt-PA in acute ischemic stroke: the CLEAR stroke trial.
    Pancioli AM; Broderick J; Brott T; Tomsick T; Khoury J; Bean J; del Zoppo G; Kleindorfer D; Woo D; Khatri P; Castaldo J; Frey J; Gebel J; Kasner S; Kidwell C; Kwiatkowski T; Libman R; Mackenzie R; Scott P; Starkman S; Thurman RJ;
    Stroke; 2008 Dec; 39(12):3268-76. PubMed ID: 18772447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TESPI (Thrombolysis in Elderly Stroke Patients in Italy): a randomized controlled trial of alteplase (rt-PA) versus standard treatment in acute ischaemic stroke in patients aged more than 80 years where thrombolysis is initiated within three hours after stroke onset.
    Lorenzano S; Toni D;
    Int J Stroke; 2012 Apr; 7(3):250-7. PubMed ID: 22292526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative Analysis on Low- and Standard-Dose Regimes of Alteplase Thrombolytic Therapy for Acute Ischemic Stroke: Efficacy and Safety.
    Zhao G; Huang T; Zheng M; Cui Y; Liu Y; Cheng Z; Wang Z
    Eur Neurol; 2018; 79(1-2):68-73. PubMed ID: 29241193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effects of low-dose versus standard-dose alteplase in ischemic patients with prior stroke and/or diabetes mellitus: The ENCHANTED trial.
    Chen G; Wang X; Robinson TG; Pikkemaat M; Lindley RI; Zhou S; Ping L; Liu W; Liu L; Chalmers J; Anderson CS;
    J Neurol Sci; 2018 Apr; 387():1-5. PubMed ID: 29571842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome of stroke patients receiving different doses of recombinant tissue plasminogen activator.
    Ong CT; Wong YS; Wu CS; Su YH
    Drug Des Devel Ther; 2017; 11():1559-1566. PubMed ID: 28572721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Risk of Hemorrhagic Transformation After Thrombolysis for Acute Ischemic Stroke in Chinese Versus North Americans: A Comparative Study.
    Xu X; Wang D; Wang F; Norton C; Liu X; Selim M
    J Stroke Cerebrovasc Dis; 2018 Sep; 27(9):2381-2387. PubMed ID: 29778315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-Dose vs Standard-Dose Alteplase for Patients With Acute Ischemic Stroke: Secondary Analysis of the ENCHANTED Randomized Clinical Trial.
    Wang X; Robinson TG; Lee TH; Li Q; Arima H; Bath PM; Billot L; Broderick J; Demchuk AM; Donnan G; Kim JS; Lavados P; Lindley RI; Martins SO; Olavarria VV; Pandian JD; Parsons MW; Pontes-Neto OM; Ricci S; Sharma VK; Thang NH; Wang JG; Woodward M; Anderson CS; Chalmers J;
    JAMA Neurol; 2017 Nov; 74(11):1328-1335. PubMed ID: 28973174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Should we exclude acute stroke patients with previous intracerebral hemorrhage from receiving intravenous thrombolysis?
    Lee SH; Kim BJ; Han MK; Park TH; Lee KB; Lee BC; Yu KH; Oh MS; Cha JK; Kim DH; Nah HW; Lee J; Lee SJ; Ko Y; Kim JG; Park JM; Kang K; Cho YJ; Hong KS; Choi JC; Kim JT; Choi K; Kim DE; Ryu WS; Kim WJ; Shin DI; Yeo M; Lee J; Lee JS; Gorelick PB; Bae HJ
    Int J Stroke; 2016 Oct; 11(7):783-90. PubMed ID: 27312681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Standard-dose intravenous tissue-type plasminogen activator for stroke is better than low doses.
    Liao X; Wang Y; Pan Y; Wang C; Zhao X; Wang DZ; Wang C; Liu L; Wang Y;
    Stroke; 2014 Aug; 45(8):2354-8. PubMed ID: 25013020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low- versus Standard-Dose Intravenous Tissue-Type Plasminogen Activator for Acute Ischemic Stroke: An Updated Meta-Analysis.
    Liu H; Zheng H; Cao Y; Pan Y; Wang D; Zhang R; You S; Zhang X; Li S; Tong X; Liu CF; Wang Y
    J Stroke Cerebrovasc Dis; 2018 Apr; 27(4):988-997. PubMed ID: 29224744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke.
    Clark WM; Wissman S; Albers GW; Jhamandas JH; Madden KP; Hamilton S
    JAMA; 1999 Dec; 282(21):2019-26. PubMed ID: 10591384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tenecteplase-tissue-type plasminogen activator evaluation for minor ischemic stroke with proven occlusion.
    Coutts SB; Dubuc V; Mandzia J; Kenney C; Demchuk AM; Smith EE; Subramaniam S; Goyal M; Patil S; Menon BK; Barber PA; Dowlatshahi D; Field T; Asdaghi N; Camden MC; Hill MD;
    Stroke; 2015 Mar; 46(3):769-74. PubMed ID: 25677596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-Dose versus Standard-Dose Intravenous Alteplase in Acute Ischemic Stroke.
    Anderson CS; Robinson T; Lindley RI; Arima H; Lavados PM; Lee TH; Broderick JP; Chen X; Chen G; Sharma VK; Kim JS; Thang NH; Cao Y; Parsons MW; Levi C; Huang Y; Olavarría VV; Demchuk AM; Bath PM; Donnan GA; Martins S; Pontes-Neto OM; Silva F; Ricci S; Roffe C; Pandian J; Billot L; Woodward M; Li Q; Wang X; Wang J; Chalmers J;
    N Engl J Med; 2016 Jun; 374(24):2313-23. PubMed ID: 27161018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose versus standard-dose intravenous alteplase for octogenerian acute ischemic stroke patients: A multicenter prospective cohort study.
    Chao AC; Han K; Lin SF; Lin RT; Chen CH; Chan L; Lin HJ; Sun Y; Lin YY; Chen PL; Lin SK; Wei CY; Lin YT; Lee JT; Hu HH; Bai CH;
    J Neurol Sci; 2019 Apr; 399():76-81. PubMed ID: 30780072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.